'A turning point for the field': 4 years after Seres failure, Finch posts positive microbiome data
In 2016, one of the first microbiome biotechs failed a major trial, cratering their stock price and casting a years-long pallor on the field. Now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
